Table 1. Patient characteristics and clinical outcome.

Patient ID	Gender	Age	Disease Subtype	Previous Treatments	Local Response	Global Response	Duration of Response (days)	Time to Progression (days)
1	M	66	PCFCL	R, I	PR	PR	169	197
2	M	59	PCMZL	I	CR	CR	189	231
3	M	46	PCLBCL	R, C, I	CR	CR	1547	1602
4	F	40	PCMZL	R	CR	SD	274+	805+
5	M	58	PCFCL	S, R	PR	PR	191+	218+
6	F	40	PCMZL	R, C	NE	NE	NA	76+
7	F	39	PCFCL	I	CR	PR	1366+	1516+
8	M	30	PCMZL	R, C, I	PR	PR	631	813
9	F	50	PCMZL	R, C	PR	PR	624	707
10	M	58	PCFCL	I	CR	SD	554+	685+
11	M	80	PCFCL	R, I	CR	SD	1150+	1280+
12	M	57	PCMZL	R, C	SD	PD	NA	79+
13	F	70	PCFCL	R, I	CR	CR	239+	349

Response corresponds to the best response of the treated lesions observed during the study. Duration of response: Number of days between the documented best response (CR, PR, MR) of treated lesions until the first date of PD is objectively documented or the date of the last visit if no progression (censored data).

Time to progression: Number of days between the date of inclusion until the first date of PD of the treated lesions is objectively documented or the date of the last visit if no progression (censored data).

NA  =  Not applicable; NE  =  non evaluable; PR  =  partial response; SD  =  stable disease; CR  =  complete response.

PCFCL  =  Primary cutaneous follicle-center lymphoma, PCMZL  =  Primary cutaneous marginal zone lymphoma.

PCLBCL  =  Primary Cutaneous Diffuse Large B-cell Lymphoma, other than leg type

R  =  Radiotherapy, S  =  Surgery, C  =  Chemotherapy, I  =  Immunotherapy including interferon, imiquimod and rituximab.

“+”in seven patients means ongoing response or non-progression at the time of study database lock.